Is AbCellera Biologics Inc. (ABCL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.7% / 30% | 51.0% / 30% | 14.7% / 30% | 37.71% / 5% | ✗ NOT HALAL |
| DJIM | 13.7% / 33% | 51.0% / 33% | 14.7% / 33% | 37.71% / 5% | ✗ NOT HALAL |
| MSCI | 10.6% / 33% | 39.3% / 33% | 11.3% / 33% | 37.71% / 5% | ✗ NOT HALAL |
| S&P | 13.7% / 33% | 51.0% / 33% | 14.7% / 33% | 37.71% / 5% | ✗ NOT HALAL |
| FTSE | 10.6% / 33% | 39.3% / 33% | 11.3% / 50% | 37.71% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -148.7% | |
| Operating Margin | -63.7% | |
| Net Margin | -194.9% | |
| Return on Equity (ROE) | -14.5% | |
| Return on Assets (ROA) | -10.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$131M |
| Free Cash Flow | -$174M |
| Total Debt | $143M |
| Debt-to-Equity | 14.8 |
| Current Ratio | 11.3 |
| Total Assets | $1.4B |
Price & Trading
| Last Close | $3.35 |
| 50-Day MA | $3.53 |
| 200-Day MA | $4.12 |
| Avg Volume | 4.1M |
| Beta | 0.9 |
|
52-Week Range
$1.89
| |
About AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AbCellera Biologics Inc. (ABCL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AbCellera Biologics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AbCellera Biologics Inc.'s debt ratio?
AbCellera Biologics Inc.'s debt ratio is 13.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.6%.
What are AbCellera Biologics Inc.'s key financial metrics?
AbCellera Biologics Inc. has a market capitalization of $991M, and revenue of $75M. The company maintains a gross margin of -148.7% and a net margin of -194.9%. Return on equity stands at -14.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.